地来西坦 | 126100-97-8

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 地来西坦
• 英文名称: Dimiracetam
• 英文别名: 2,5-dioxohexahydro-1H-pyrrolo[1,2-a]imidazole；tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione；3,6,7,7a-tetrahydro-1H-pyrrolo[1,2-a]imidazole-2,5-dione
• CAS: 126100-97-8
• 化学式: C₆H₈N₂O₂
• mdl: MFCD00867777
• 分子量: 140.142
• InChiKey: XTXXOHPHLNROBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 储存条件：
  存储条件：2-8°C，密封，干燥。

制备方法与用途

迪米拉西坦是一种口服活性化合物，具有抗神经性作用。在冷刺激大鼠模型中，迪米拉西坦能够抑制超敏反应和神经系统改变，并能抑制索拉非尼（HY-10201）诱导的神经病变。

反应信息

• 作为反应物：
  描述：

  地来西坦 在 N-甲基吡咯烷酮 、 copper(l) iodide 、 potassium carbonate 作用下， 反应 0.33h， 生成 1-(2,6-dimethyl-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione
  参考文献：
  名称：

  [EN] PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS
  [FR] COMPOSES PRESENTANT UNE ACTION NOOTROPIQUE, LEUR PREPARATION, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, ET LEUR UTILISATION

  摘要：

  公开号：

  WO2004085438A3
• 作为产物：
  描述：

  methyl 1-benzyl-4-oxo-2-imidazolidinepropanoate 在 palladium on activated charcoal ammonium formate 作用下， 以 甲醇 、 水 为溶剂， 反应 3.0h， 以81%的产率得到地来西坦
  参考文献：
  名称：

  Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers

  摘要：

  A series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones were synthesized. These bicylic derivatives contain both the 2-pyrrolidinone and 4-imidazolidinone nuclei, already recognized as important for cognition enhancing activity. In addition, these structures maintain the backbone of piracetam and oxiracetam with the acetamide side chain restricted in a folded conformation. Their ability to reverse scopolamine-induced amnesia was assessed in a one trial, step-through, passive avoidance paradigm. The main features observed are a potent antiamnestic activity after ip administration (minimal effective dose being between 0.3 and 1 mg/kg ip for most compounds), the presence of a bell-shaped dose-response curve and, generally, a reduction of biological activity after po administration. However, the unsubstituted compound (15, dimiracetam) shows no evidence of a bell-shaped dose-response curve and completely retains activity when given orally, being 10-30 times more potent than the reference drug oxiracetam.

  DOI：

  10.1021/jm00078a011

文献信息

• [EN] (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS<br/>[FR] (R)-4-((4-((4-(TÉTRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)MÉTHYL) PIPÉRIDIN-1-YL)MÉTHYL)TÉTRAHYDRO-2H-PYRAN-4-OLE, AGONISTE PARTIEL DES RÉCEPTEURS 5-HT4
  申请人：PFIZER

  公开号：WO2011101774A1

  公开（公告）日：2011-08-25

  (R)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3- yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol and its use in treating neurodegenerative disorders, is described herein.

  (R)-4-((4-((4-(四氢呋喃-3-氧基)苯并[d]异噁唑-3-氧基)甲基)哌啶-1-基)甲基)四氢-2H-吡喃-4-醇及其在治疗神经退行性疾病中的用途在此描述。
• [EN] CANNABINOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS DES CANNABINOÏDES
  申请人：ARENA PHARM INC

  公开号：WO2012116279A1

  公开（公告）日：2012-08-30

  Provided are certain methods useful in the treatment of pain comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor.

  提供了一些在治疗疼痛方面有用的方法，包括给予化合物Ia的复方及其药物组合物，以调节大麻素CB2受体的活性。
• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• AMINOCYCLOBUTANE DERIVATIVES, METHOD FOR PREPARING SAME AND THE USE THEREOF AS DRUGS
  申请人：PIERRE FABRE MEDICAMENT

  公开号：US20150315132A1

  公开（公告）日：2015-11-05

  The present inventions concerns derivatives of aminocyclobutane, particularly as NMDA receptor antagonists, their application in human therapy and their method of preparation. These compounds correspond to the general formula (1): wherein: X 1 represents a hydrogen atom or fluorine atom; X 2 is a hydrogen atom or fluorine atom or chlorine atom; R1 represents a hydrogen atom or fluorine atom or chlorine atom or methyl group or methoxy group or cyano group; R2 represents independently or together a methyl group or ethyl group.

  目前的发明涉及氨基环丁烷的衍生物，特别是作为NMDA受体拮抗剂，在人类治疗中的应用以及它们的制备方法。这些化合物对应于一般式（1）：其中：X1代表氢原子或氟原子；X2是氢原子或氟原子或氯原子；R1代表氢原子或氟原子或氯原子或甲基基团或甲氧基团或氰基；R2独立或一起代表甲基基团或乙基基团。